Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Axonal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    46 result(s) found for: Axonal. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2008-005656-24 Sponsor Protocol Number: EM-OCT-01 Start Date*: 2008-12-29
    Sponsor Name:Dra. Rosario Blasco
    Full Title: ENSAYO CLÍNICO SOBRE LA EVOLUCIÓN Y EL IMPACTO DEL TRATAMIENTO FARMACOLÓGICO EN LA PERDIDA AXONAL PROGRESIVA EN PACIENTES QUE CON ESCLEROSIS MÚLTIPLE QUE HAN PRESENTADO UN PRIMER EPISODIO DESMIELIN...
    Medical condition: Primer episodio desmielinizante con criterios de esclerosis múltiple (EM) confirmada por laboratorio que no haya consistido en neuritis óptica y que no tengan criterios de mal pronóstico definidos ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001824-23 Sponsor Protocol Number: CME-LEC1 Start Date*: 2017-11-29
    Sponsor Name:Fundación de Investigación Biomédica del Hospital Universitario Puerta de Hierro-Majadahonda (FIBM-HUPHM)
    Full Title: Intrathecal administration of autologous adult bone marrow mesenchymal stem cells expanded in the diffuse axonal injury.
    Medical condition: Traumatic cerebral injury, chronically established attributed to diffuse axonal injury.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001253-13 Sponsor Protocol Number: ROCHIMS Start Date*: 2017-08-23
    Sponsor Name:UZ Brussel
    Full Title: Does cerebral hypoperfusion play a role in reduced axonal metabolism and clinical disability in patients with multiple sclerosis ?
    Medical condition: Patients suffering relapsing- remitting multiple sclerosis will be investigated in this study, with an EDSS score less or equal to 4.0. Patients must be older than 18 years old. There must not be a...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023996-25 Sponsor Protocol Number: 26081985 Start Date*: 2010-12-21
    Sponsor Name:
    Full Title: The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis.
    Medical condition: Multiple sclerosis (both relapsing remitting and progressive forms)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001340-25 Sponsor Protocol Number: UMC-NMZ-EPHENE2020 Start Date*: 2020-07-17
    Sponsor Name:University Medical Center Utrecht
    Full Title: Enrichment randomized double-blind, placebo-controlled cross-over trial with PHEnytoin cream in patients with painful chronic idiopathic axonal polyNEuropathy
    Medical condition: Painful chronic idiopathic axonal polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10040040 Sensory polyneuropathy axonal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002982-38 Sponsor Protocol Number: 27025 Start Date*: 2006-11-29
    Sponsor Name:Merck Serono S.A.-Geneva, an affiliate of Merck KGaA Darmstadt, Germany
    Full Title: A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis
    Medical condition: Subjects at high risk of converting to Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.0 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) AT (Completed) LT (Prematurely Ended) SK (Completed) DE (Completed) FI (Completed) FR (Completed) EE (Completed) DK (Completed) IT (Completed) GR (Completed) PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-015007-97 Sponsor Protocol Number: DEFENCE Start Date*: 2010-02-16
    Sponsor Name:DR. ENRICO MONTANARI
    Full Title: Retinal Nerve Fiber Layer (RNFL) as measured by Optical Coherence Tomography (OCT) to Depict axonal loss in Early RRMS treated with difFEreNt dosage of subCutaneous IFN bEta 1a
    Medical condition: Patients with RR-MS diagnosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003056-36 Sponsor Protocol Number: CBAF312A2304 Start Date*: 2012-10-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro...
    Medical condition: Secondary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) IE (Completed) DE (Prematurely Ended) CZ (Completed) SK (Completed) NL (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Completed) SE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) LV (Completed) GR (Completed) LT (Completed) EE (Completed) BE (Prematurely Ended) PL (Completed) BG (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002631-42 Sponsor Protocol Number: MS700568_0022 Start Date*: 2018-04-18
    Sponsor Name:Merck KGaA
    Full Title: A 2-year prospective study to evaluate the onset of action of Mavenclad® in subjects with highly active relapsing multiple sclerosis
    Medical condition: Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) AT (Completed) CZ (Completed) ES (Completed) FR (Completed) BE (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003001-94 Sponsor Protocol Number: MSGLP Start Date*: 2019-11-06
    Sponsor Name:Lekárska fakulta UK Bratislava
    Full Title: Use of GLP-1 analogs in the treatment of multiple sclerosis
    Medical condition: Our hypothesis is that patients with MS have a disorder of energy metabolism in neurons and glial cells of the CNS, contributing to the development and progression of demyelinating foci and neurode...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023021-38 Sponsor Protocol Number: STRIX-MS001 Start Date*: 2011-02-23
    Sponsor Name:Västerbottens läns landsting
    Full Title: Switch To RItuXimab in MS A phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy approach
    Medical condition: Relapsing-remitting multiple sclerosis in stable condition while treated with first line injectible disease-modifying drugs (DMDs), eg beta-interferons or glatiramere acetate
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000721-31 Sponsor Protocol Number: RIDOSE-MS Start Date*: 2018-07-04
    Sponsor Name:Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital
    Full Title: RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MS A randomized trial of long-term dosage of rituximab in multiple sclerosis The RIDOSE-MS trial is a multi-centre trial of long-term ...
    Medical condition: Patients with multiple sclerosis (MS), 20 - 52 years of age, that have completed the RIFUND-MS trial (EudraCT 2015-004116-38) will be offered to continue in this extension trial, RODOSE-MS. In addi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001509-21 Sponsor Protocol Number: B7981037 Start Date*: 2020-12-08
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF 06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA
    Medical condition: Alopecia areata
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10001761 Alopecia areata PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005947-22 Sponsor Protocol Number: SIPO20 Start Date*: 2021-11-17
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Effect of siponimod on relevant imaging and immunological hallmarks of progressive multiple sclerosis
    Medical condition: Active progressive MS course after an initial relapse clinical course
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004116-38 Sponsor Protocol Number: RIFUND-MS Start Date*: 2015-12-18
    Sponsor Name:Department of Clinical Sciences, Danderyd Hospital
    Full Title: RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis – RIFUND-MS A randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis Ob...
    Medical condition: Patients with multiple sclerosis (MS) or patients presenting with symptoms highly suspicious of MS while not completely fulfilling diagnostic criteria, 18 - 50 years of age and no more than 10 year...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016442-74 Sponsor Protocol Number: CMM-EM Start Date*: Information not available in EudraCT
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Trasplante autólogo de células madre mesenquimales en esclerosis múltiple: ensayo clínico fase II aleatorizado, enmascarado y cruzado con placebo.
    Medical condition: Esclerosis Múltiple
    Disease: Version SOC Term Classification Code Term Level
    9 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023264-40 Sponsor Protocol Number: SNC Start Date*: 2010-10-21
    Sponsor Name:AZIENDA OSPEDALIERA S. GERARDO DI MONZA
    Full Title: Efficacy in the central nervous system (CNS) of two combination regimens with different penetration rank in HIV-positive na�ve patients
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049072 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001949-42 Sponsor Protocol Number: BRD50 Start Date*: 2005-09-08
    Sponsor Name:University College London
    Full Title: A randomised controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002515-10 Sponsor Protocol Number: P000053 Start Date*: 2014-07-18
    Sponsor Name:University Medical Center Freiburg
    Full Title: Treatment of Optic Neuritis with Erythropoietin: a randomised, double-blind, placebo-controlled trial
    Medical condition: Optic Neuritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004172-30 Sponsor Protocol Number: PREPARE Start Date*: 2021-10-13
    Sponsor Name:Charité – Universitätsmedizin Berlin
    Full Title: Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemothe...
    Medical condition: Breast cancer patients scheduled for treatment with paclitaxel chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 14:26:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA